Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics

Go online to PeerView.com/YJX860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. New insight into the biology of myelofibrosis (MF) led to
the validation of effective JAK inhibitor–based treatment
platforms, setting the stage for subsequent therapeutic advances in
this difficult-to-treat myeloproliferative neoplasm. The emergence
of newer JAK inhibitor options has fueled additional research on
newer mechanisms of action that may soon play a role in conjunction
with JAK-based platforms as part of sequential or combination
therapy. In this activity, based on a recent live event, expert
panelists provide guidance on leveraging these developments when
planning care for patients with a variety of comorbid conditions,
prognostic features, or treatment experiences. Join the experts now
and take your patient care to the next level! Upon completion of
this activity, participants should be better able to: Summarize
characteristics of myelofibrosis (MF) that are relevant for therapy
selection, prognosis, and the use of modern risk assessment models;
Cite current evidence on the use of JAK inhibitor platforms and
emerging targeted agents in MF management, including as frontline
or sequential treatment, in pre-HCT strategies, or in
treatment-refractory disease; Integrate modern targeted options
into the personalized upfront and sequential management of patients
with MF; and Manage safety considerations associated with the use
of targeted therapy platforms in MF.